These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 26587548)

  • 1. Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy.
    Huang MA; Krishnadas DK; Lucas KG
    J Immunol Res; 2015; 2015():675269. PubMed ID: 26587548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
    Lin C; Zhang J
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NK cell-based immunotherapy for cancer.
    Fang F; Xiao W; Tian Z
    Semin Immunol; 2017 Jun; 31():37-54. PubMed ID: 28838796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on the current revolution in cancer immunotherapy.
    Renrick AN; Dunbar ZT; Shanker A
    Immunotherapy; 2019 Jan; 11(1):15-20. PubMed ID: 30702010
    [No Abstract]   [Full Text] [Related]  

  • 5. Strategies for combining immunotherapy with radiation for anticancer therapy.
    Seyedin SN; Schoenhals JE; Lee DA; Cortez MA; Wang X; Niknam S; Tang C; Hong DS; Naing A; Sharma P; Allison JP; Chang JY; Gomez DR; Heymach JV; Komaki RU; Cooper LJ; Welsh JW
    Immunotherapy; 2015; 7(9):967-980. PubMed ID: 26310908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer Immunotherapy: Theory and Application.
    Chen G; Bodogai M; Tamehiro N; Shen C; Dou J
    J Immunol Res; 2018; 2018():7502161. PubMed ID: 30035133
    [No Abstract]   [Full Text] [Related]  

  • 8. Active Immunotherapy of Cancer.
    Chodon T; Koya RC; Odunsi K
    Immunol Invest; 2015; 44(8):817-36. PubMed ID: 26575466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.
    Liu D; Tian S; Zhang K; Xiong W; Lubaki NM; Chen Z; Han W
    Protein Cell; 2017 Dec; 8(12):861-877. PubMed ID: 28488245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future.
    Steendam CM; Dammeijer F; Aerts JGJV; Cornelissen R
    Immunotherapy; 2017 May; 9(6):507-520. PubMed ID: 28472903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral and cellular immunotherapy in ALL in children, adolescents, and young adults.
    Hochberg J; El-Mallawany NK; Cairo MS
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S6-13. PubMed ID: 25486958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for pediatric cancer.
    Grupp SA; Verneris M; Sondel PM; Cooper LJ
    Biol Blood Marrow Transplant; 2008 Jan; 14(1 Suppl 1):33-43. PubMed ID: 18162219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Advances in immunotherapy for pediatric cancer].
    Xu X; Zhao H; Tang Y
    Zhonghua Er Ke Za Zhi; 2014 Mar; 52(3):231-4. PubMed ID: 24824398
    [No Abstract]   [Full Text] [Related]  

  • 14. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
    Davis ZB; Vallera DA; Miller JS; Felices M
    Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.
    Zhukovsky EA; Morse RJ; Maus MV
    Curr Opin Immunol; 2016 Jun; 40():24-35. PubMed ID: 26963133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular therapy of cancer with natural killer cells-where do we stand?
    Klingemann HG
    Cytotherapy; 2013 Oct; 15(10):1185-94. PubMed ID: 23768925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.
    Khalil DN; Smith EL; Brentjens RJ; Wolchok JD
    Nat Rev Clin Oncol; 2016 May; 13(5):273-90. PubMed ID: 26977780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging role of immunotherapy for childhood cancers.
    Handgretinger R; Schlegel P
    Chin Clin Oncol; 2018 Apr; 7(2):14. PubMed ID: 29764159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy.
    Hu Y; Tian ZG; Zhang C
    Acta Pharmacol Sin; 2018 Feb; 39(2):167-176. PubMed ID: 28880014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunotherapy for cancer--modern immunologic strategies in oncology].
    Halama N; Zoernig I; Jäger D
    Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.